MolDX: Blood Product Molecular Antigen Typing

Molecular blood product antigen typing is covered for pre-transfusion evaluation when patients are expected to require long-term frequent transfusions, when serologic reactivity or autoantibodies prevent exclusion of clinically significant alloantibodies, when typing sera are unavailable for a suspected antibody, or when serologic typing discrepancies exist. Testing is not expected for routine perioperative transfusions or for patients with serologically identifiable alloantibodies who will not need long-term transfusion; single-gene tests are generally not covered except in rare, documented cases. Medical necessity must be documented in the medical record, tests considered germline must comply with germline testing policies, and LDTs require evidence of equivalent or superior validity and clinical utility demonstrated by a technical assessment.

"Molecular phenotyping of blood product antigens is covered for pre-transfusion evaluation when long-term, frequent transfusions are anticipated to prevent alloantibody development (e."